There are almost one hundred inborn errors of metabolism which can start in the neonatal period, but less than 20 are amenable to treatment. In general, an extremely evocative clinical setting is the course of a full-term baby born after normal pregnancy and delivery who, after an initial symptom-free period deteriorates relentlessly for no apparent reason and does not respond to symptomatic therapy. Investigations routinely performed in all sick neonates yield normal results. Emergency treatment must be undertaken in parallel with investigations. Five main presentations can be observed: a neurologic deterioration 'intoxication' type mostly suggests maple syrup urine disease, methylmalonic, propionic, isovaleric acidaemias and urea cycle disorders. Isolated seizures is the revealing symptom of pyridoxine-responsive and folinic acid responsive seizures. A jaundice or a liver failure suggest galactosaemia, fructosaemia, tyrosinaemia type I (after 3 weeks), phosphomannoisomerase deficiency or bile acid synthesis defects. Cardiac failure and heartbeat disorders should first suggest mitochondrial fatty acid oxidation (FAO) disorders. Persistent hypoglycaemia is the presenting sign of glyco/ gluconeogeneis defects, hyperinsulinism and FAO disorders. The first line investigation relies upon the collection at the same time of a few samples including blood gases electrolytes, prothrombin time, transaminases, ammonia and lactic acid, and the search for ketonuria. The storage of plasma, urine and blood (on filter paper) is an important element in the diagnosis. The utilization of these samples should be carefully planned after taking advice from specialists in inborn errors.
Introduction
Inborn errors of metabolism are individually rare but collectively numerous. With the recent application of tandem mass spectrometry (tandem MS) to the field of newborn screening for inherited diseases, the neonatologist will be the first to have the opportunity to provide early treatment of these disorders of fat oxidation, organic acidurias and some aminoacidopathies. This aspect of prospective treatment before any clinical symptoms is presented in Chapter 4.
However, at this moment, as a whole, many inborn errors cannot be recognized through systematic neonatal screening tests which are too slow, too expensive or unreliable. Clinical diagnosis of inborn errors of metabolism in neonates relies upon a limited number of rules: 1. Think about them in parallel to other more common conditions (such as sepsis). 2. As the neonate has an apparently limited repertoire of responses to severe overwhelming illness, the predominant clinical signs and symptoms can be nonspecific like poor feeding, lethargy, failure to thrive, etc. 3. Think systematically about these inborn errors of metabolism which are amenable to treatment -mostly inborn errors of 'intoxication' type - (Table 1 ). 4. Although most genetic metabolic errors are hereditary and are transmitted as recessive disorders, the majority of cases appear to be sporadic and should be recognized as early as the first birth. 5. An adequate diagnostic approach can be based on the proper use of only a few screening tests (Table 4) . 6 . As soon as the diagnosis is suspected, an emergency management has to be scheduled even if precise diagnosis is still unknown (Chapter 2). Based mostly upon personal experience of more than 700 patients over 30 years, this chapter gives an overview of clinical keys to the diagnosis of inborn errors of metabolism in neonates [1, 2] .
Classification
Despite their diversity, the metabolic disorders can be divided into the following three diagnostically useful groups.
Group 1: Disorders that give rise to intoxication
This group includes inborn errors of intermediary metabolism that lead to an acute or progressive intoxication from accumulation of toxic compounds proximal to the metabolic bloc. In this group are the aminoacidopathies like maple syrup urine disease or tyrosinaemia type I, most organic acidaemias like methylmalonic, propionic or isovaleric acidaemias, congenital urea cycle defects, and sugar intolerances (galactosaemia, hereditary fructose intolerance). All the conditions in this group present clinical similarities, including a symptom-free interval followed by clinical signs of 'intoxication', like vomiting, lethargy, coma, liver failure, etc. Biological diagnosis is easy and relies mostly on plasma and urine amino-or organicacid chromatography. Many of these disorders are treatable and require an early intervention aiming at removal of the toxin by special diets, exchange transfusion, peritoneal dialysis, or haemodiafiltration.
Group 2: Disorders involving energy metabolism
This group consists of inborn errors of intermediary metabolism with symptoms due at least partly to a deficiency in energy production or utilization resulting form a defect in the liver, myocardium, muscle, or brain. Included in this group are disorders presenting as a predominant hypoglycaemia like glycogenosis, gluconeogenesis defects and hyperinsulinism, the fatty acid oxidation disorders, and the congenital lactic acidaemias (deficiencies of pyruvate carboxylase, pyruvate dehydrogenase, Krebs cycle and mitochondrial respiratory chain disorders). Symptoms common to this group include failure to thrive, severe hypoglycaemia, hyperlactacidaemia, severe generalized hypotonia, myopathy, cardiomyopathy, cardiac failure, arrhythmias, conduction defects, circulatory collapse, sudden infant death, dysmorphia and malformations. Most of the disorders presenting with hypoglycaemia are at least partly amenable to treatment while congenital lactic acidaemias are in general not treatable.
Group 3: Disorders involving complex molecules
This group includes diseases that disturb the synthesis or the catabolism of complex molecules. Symptoms are permanent, progressive, independent of intercurrent events, and are not related to food intake. All lysosomal disorders, peroxisomal disorders, disorders of intracellular trafficking and processing (such as -1-antitrypsin deficiency and congenital defects of glycosylation [CDG syndrome]), and inborn errors of cholesterol synthesis belong to this group. Almost none of these disorders are treatable in emergency.
Clinical presentation

General considerations
The neonate has a limited repertoire of responses to severe illness and, at first, present with nonspecific symptoms such as respiratory distress, hypotonia, poor sucking reflex, vomiting, diarrhoea, dehydration, lethargy or seizures, all symptoms that could easily be attributed to infection or some other common cause. If these symptoms are present, the deaths of affected siblings may have been falsely attributed to sepsis, heart failure or intraventricular haemorrage, and it is important to review clinical records and autopsy records critically when they are available. Of special interest is the observation that these disorders are not usually associated with prematurity. Most of the reported cases were full term neonates.
In the intoxication type of metabolic distress, an extremely evocative clinical setting is the course of a full-term baby born after normal pregnancy and delivery who, after an initial symptom-free period during which the baby is completely normal, deteriorates relentlessly for no apparent reason and does not respond to symptomatic therapy. The interval between birth and clinical symptoms may range from hours to weeks, depending on the nature of the metabolic block and the environment.
Investigations routinely performed in all sick neonates, including chest X-ray, cerebrospinal fluid (CSF) examination, 'septic' screen, and cerebral ultrasound yield normal results. This unexpected and 'mysterious' deterioration of a child after a normal initial period is the most important signal of the presence of an inherited disease of the intoxication type. If present, careful re-evaluation of the child's condition is warranted. Signs previously interpreted as nonspecific manifestations of neonatal hypoxia, infection or other common diagnoses take on a new significance in this context. In energy deficiencies, mostly those presenting with congenital lactic acidaemia, clinical presentation is often less evocative and displays variable severity. However, in these disorders presenting with a predominant hypoglycaemia, clinical findings are often highly suggestive (obvious hepatomegaly in glycogenosis and gluconeogenesis defects, myocardiopathy, cardiac failure, heart beat disorders and sudden death in fatty acid oxidation disorders, recurrent intractable hypoglycaemia in hyperinsulinism). An algorithm for screening treatable inborn errors of metabolism in sick neonates is summarized in Table 1 .
Neurologic deterioration (coma, lethargy)
Most inborn errors of both the intoxication or energy-deficiency types are brought to a doctor's attention because of neurologic deterioration. In the intoxication type, the initial symptom-free interval varies in duration depending on the condition. Typically, the first reported sign is poor sucking and feeding, after which the child sinks into an unexplained coma despite supportive measures. At a more advanced state, neurovegetative problems with respiratory abnormalities, hiccups, apnoeas, bradycardia, and hypothermia can appear. In the comatose state, characteristic changes in muscle tone and involuntary movements appear. Generalized hypertonic episodes with opisthotonus are frequent, and boxing or pedalling movements and slow limb elevations, spontaneously or upon stimulation, are observed. Conversely, most nonmetablic causes of coma are associated with hypotonia, so the presence of 'normal' peripheral muscle tone in a comatose child reflects a relative hypertonia. Another neurologic pattern suggesting metabolic disease is axial hypotonia and limb hypertonia with large-amplitude tremors and myoclonic jerks, which are often mistaken for convulsions. An abnormal urine and body odour is present in some diseases in which volatile metabolites accumulate. If one of the preceding symptoms is present, treatable metabolic disorders -i.e. maple syrup urine disease, methylmalonic, propionic, isovaleric acidaemias, multiple carboxylase deficiency and urea cycle disorders -should be given a high diagnostic priority. The diagnosis of these disorders relies upon plasma and urine amino acid and organic acid chromatographies or on plasma acylcarnitine profile (by tandem MS-MS from a blood spot collected on a Guthrie test).
In energy deficiencies, the clinical presentation is less evocative and displays a more variable severity. In many conditions, there is no symptom-free interval. The most frequent symptoms are a severe generalized hypotonia, rapidly progressive neurologic deterioration, possible dysmorphia, and malformations. However, in contrast to the intoxication group, lethargy and coma are rarely inaugural signs. Hyperlactacidaemia with or without metabolic acidosis is a very frequent symptom. Cardiac symptoms and hepatic symptoms are frequently associated (below).
Only a few lysosomal disorders with storage symptoms are expressed in the neonatal period. By contrast, most peroxisomal disorders present immediately after birth, with dysmorphia and severe neurological dysfunction. Unfortunately, none of these disorders are amenable to an efficient urgent treatment.
Seizures
Inaugural and isolated convulsions are rather rare in inborn errors of intermediary metabolism with the exception of pyrixodine-dependent seizures, folinic Table 1 . 'Sick' neonate: an algorithm to screen treatable inborn errors of metabolism CDG = congenital disorders of glycosylation; FAO = fatty acid oxidation disorders; IVA = isovaleric acidaemia; MCD = multiple carboxylase definciency; MMA = methylmalonic aciduria; MSUD = maple syrup urine disease; PA = propionic acidaemai; UCD = urea cycle defects. [3, 4, 5] . Interestingly, a special face has been described in hyperinsulinism (Chapter 9).
Hepatic presentation
Four main clinical groups of hepatic symptoms can be identified (for details, see Chapter 5):
Hepatomegaly with hypoglycaemia and seizures suggest glycogenosis types I and III, gluconeogenesis defects, or severe hyperinsulinism.
Liver failure syndrome (jaundice, haemorrhagic syndrome, hepatocellular necrosis with elevated transaminases, and hypoglycaemia with ascites and edema) suggests hereditary fructose intolerance (in the case of a fructosecontaining diet), galactosaemia, tyrosinosis type I (after 3 weeks), neonatal haemochromatosis, and respiratory chain disorders. A new disorder has been recently described in 15 newborns from Finland, who all presented with severe fetal growth retardation, lactic acidosis, failure to thrive, hyperaminoaciduria, very high serum ferritin, haemosiderosis of the liver, and early death. The aetiology of this syndrome is unknown [6] .
Predominantly cholestatic jaundice with failure to thrive is observed in -1-antitrypsin deficiency, Byler disease, inborn errors of bile acid metabolism, peroxisomal disorders, Niemann-Pick type C disease, CDG syndrome [7, 8] and cholesterol biosynthesis defects.
Hepatosplenomegaly is a feature of lysosomal storage disorders (Chapters 5 and 7).
Cardiac presentation
Sometimes metabolic distress can strike with predominant cardiac symptoms. Cardiac failure revealing or accompanying a cardiomyopathy (dilated hypertrophic) and most often associated with hypotonia, muscle weakness, and failure to thrive, suggests respiratory chain disorders, Pompe disease or fatty acid oxidation disorders. Recent observations suggest that some respiratory chain disorders are tissue specific and are only expressed in the myocardium. CDG syndrome can sometimes present in infancy, with cardiac failure due to pericardial effusions, cardiac tamponade, and cardiomyopathy. Many defects of long chain fatty 
Diagnostic tests Initial approach
Once clinical suspicion of an inborn metabolic error is aroused, general supportive measures and laboratory investigations must be undertaken simultaneously (Table 4) . Abnormal urine odours can be detected from a drying filter paper or by opening a container of urine that has been closed at room temperature for a few minutes. The most important examples are the maple syrup odour of MSUD and the sweaty-feet odour of isovaleric acidaemia (IVA) and type II glutaric acidaemia (GA). Although serum ketone bodies reach 0.5-1 mmol/l in early neonatal life, acetonuria, if observed in a newborn, is always abnormal and an important sign of metabolic disease. The dinitrophenylhydrazine (DNPH) test screens for the presence of -keto acids, such as seen in MSUD. The test can be considered significant only in the absence of glucosuria and acetonuria, which also react with DNPH. Hypocalcaemia and elevated or reduced blood glucose are frequently present in metabolic diseases. The physician should be cautious of attributing marked neurologic dysfunction merely to these findings.
The metabolic acidosis of organic acidurias is usually accompanied by an elevated anion gap. Urine pH should be below 5; otherwise, renal acidosis is a consideration. A normal serum pH does not exclude hyperlactacidaemia, as neutrality is usually maintained until serum levels exceed 5 mmol/l. Ammonia and lactic acid should be determined systematically in newborns at risk. An elevated ammonia level in itself can induce respiratory alkalosis; hyperammonaemia with ketoacidosis suggests an underlying organic acidaemia. Elevated lactic acid levels in the absence of infection or tissue hypoxia are a significant finding. Moderate elevations (3-6 mmol/l) are often observed in organic acidaemias and in the hyperammonaemias; levels greater than 10 mmol/l are frequent in hypoxia. It is important to measure lactate (L), pyruvate (P), 3-hydroxyburytate (3OHB), and acetoacetate (AA) on a plasma sample immediately deproteinized at the bedside in order to appreciate cytoplasmic and mitochondrial redox states through the measurement of L/P and 3OHB/AA ratios, respectively [11] . Some organic acidurias induce granulocytopenia and thrombocytopenia, which may be mistaken for sepsis. The storage of adequate amounts of plasma, urine, blood (on filter paper), and CSF is an important element in diagnosis. The utilization of these precious samples should be carefully planned after taking advice from specialists in inborn errors of metabolism.
Once the above clinical and laboratory data have been assembled, specific therapeutic recommendations can be made (Chapter 2). This process is completed within 2-4 hours and often precludes long waiting periods for sophisticated diagnostic results. On the basis of this evaluation, most patients can be classified into one of five groups (Table 5 ). The experienced clinician will, of course, have to carefully interpret the metabolic data, especially in relation to time of collection and ongoing treatment. It is important to insist on the need to collect at the same time all the biologic data listed in Table 2 . Some very significant symptoms (such as metabolic acidosis and especially ketosis) can be moderate and transient, largely depending on the symptomatic therapy. Conversely, at an advanced state, many nonspecific abnormalities (such as respiratory acidosis, severe hyperlactacidaemia, or secondary hyperammonaemia) can disturb the original metabolic profile. This applies particularly to disorders with rapid fatal course, such as urea cycle disorders, in which the initial characteristic presentation of hyperammonaemia with respiratory alkalosis and without ketosis shifts rapidly to a rather nonspecific picture of acidosis and hyperlactacidaemia. 
Five major types of metabolic distress
According to the major clinical presentations and the proper use of the laboratory data described above, most patients can be schematically assigned to one of five syndromes. In our experience, type I (MSUD), type II (organic acidurias), type IV a (urea cycle defects), type IV b (NKH, respiratory chain and FAO disorders) encompass more than 80% of the newborn infants with inborn errors of intermediary metabolism presenting with a neurologic deterioration.
Type I: Predominant ketosis
Neurologic deterioration of the intoxication type with ketosis is represented by MSUD. It is one of the most common aminoacidopathies (Chapter 6).
Type II: Predominant ketoacidosis (with hyperammonaemia)
Neurologic deterioration of the intoxication type with ketoacidosis and hyperammonaemia encompasses many of the organic acidurias (Chapter 6). In addition to methylmalonic (MMA), propionic (PA) and isovaleric (IVA) acidaemias, which mostly present with ketoacidosis, a large number of rare organic acidurias have been uncovered in recent years as sophisticated organic acid analysis techniques have become more available. Among them, GA type II or multiple acylCoA dehydrogenase deficiency, long-chain FAO defects, and 3-hydroxy-3-methylglutaryl (HMG)-CoA lyase deficiency have many similarities with MMA, PA, and IVA, except that ketosis is absent and hypoglycaemia is frequent. FAO disorders frequently present with cardiac symptoms and moderate liver dysfunction and can be responsible for sudden death. Very rare conditions in this group are succinyl-CoA transferase deficiency, biotindependent multiple carboxylase deficiency (MCD) due to holoenzyme synthetase deficiency, shortchain acyl-CoA dehydrogenase (SCAD) deficiency, 3-methylglutaconicuria, and glycerol kinase deficiency, which all display ketoacidosis. Pyroglutamic aciduria is a rare condition that can start in the first few days of life with a severe metabolic acidosis but without ketosis or abnormalities of blood glucose, lactate, or ammonia. The final diagnosis of all these organic acidurias is made by identifying specific abnormal metabolites by gas chromatography-mass spectrometry (GCMS) of plasma and urine, or by investigating the acylcarnitine profile of a blood spot collected on a filter paper by tandem MS-MS or ordinary MS.
Type III: Predominant lactic acidosis with neurological distress of the energy deficiency type
The clinical presentation of these children varies. Unlike the previous disease category, in which moderate acidosis is noted during the evaluation of an acutely ill, comatose child, the main medical preoccupation in group III patients is the acidosis itself, which clinically may be surprisingly well tolerated. The acidosis can sometimes be mild. An elevated anion gap exists, which can be explained in part by the presence of equimolar amounts of lactic acid in the blood. Often the acidosis recurs soon after bicarbonate therapy, in the absence of adequate treatment. If a high lactic acid concentration is found, it is urgent that readily treatable causes, especially hypoxia, be ruled out. Ketosis is present in most of the primary lactic acidaemias but is absent in acidosis secondary to tissue hypoxia. Biotinresponsive MCD may present as lactic acidosis, and biotin therapy is indicated in all patients with lactic acidosis of unknown cause after baseline blood and urine samples have been taken. Primary lactic acidoses form a complex group. A definite diagnosis is often elusive and is attained with specific enzyme assays and by considering metabolite levels, redox potential states, and fluxes under fasting and fed conditions [11] . However, many cases remain unexplained.
Type IVa: Neurologic distress of the intoxication type with hyperammonaemia and without ketoacidosis
Type IV is divided into two groups: IVa and IVb. Type IVa encompasses urea cycle defects and triple H. As mentioned above, this group of patients is one of the most important among those with neonatal inborn errors of metabolism. A diagnostic clue to separate urea cycle defects from organic acidurias with hyperammonaemia is the universal absence of ketonuria in the former group. As already stated, at an advanced state, neurovegetative disorders rapidly give rise to nonspecific findings including acidosis and hyperlactacidaemia. An elusive diagnostic consideration is transient hyperammonaemia of the neonate (Chapter 3).
Long-chain FAO disorders (mainly carnitine palmitoyltransferase II (CPT II), and carnitine translocase deficiencies) can also (though rarely) present in the neonatal period with hyperammonaemia and mimic urea cycle disorders. They are usually associated with hypoglycaemia, hepatic dysfunction, muscular and cardiac symptoms, or sudden infant death (Chapter 4).
Type IVb: Neurologic deterioration without ketoacidosis and without hyperammonemia
The most frequent diseases of type IVb are NKH, SO, and inborn errors of peroxisomal metabolism (Chapter 8). SO is probably underdiagnosed, as its clinical pattern shares many similarities with common acute fetal distress. In addition, some patients with respiratory chain disorders can present in the neonatal period without evidence of lactic acidosis. Beside these four disorders, an increasing number of other rare conditions has been described in recent years, including neurotransmitter disorders, CDG syndrome, and cholesterol biosynthesis defects, and we can assume that the list of disorders of this group will expand substantially in the near future.
FAO disorders can also be observed in the neonatal period without acidosis or hyperammonaemia. They present with hypoglycaemia, hepatic dysfunction possibly associated with muscular and cardiac symptoms, or sudden infant death. Trifunctional enzyme deficiency can be revealed by severe hypotonia and neurologic distress without obvious metabolic disturbances.
Type V: Hepatomegaly and liver dysfunction
In this type, four main clinical groups of hepatic symptoms lead to the diagnosis of more than 20 inborn errors of metabolism (Table 5 , Chapter 5).
